{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:57:06Z","timestamp":1774943826037,"version":"3.50.1"},"reference-count":37,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2018\/316"],"award-info":[{"award-number":["CAN2018\/316"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00651"],"award-info":[{"award-number":["2022-00651"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["FoUI-974833"],"award-info":[{"award-number":["FoUI-974833"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Methylphenidate can be used for the treatment of cancer-related fatigue (CRF), although randomized controlled trials have shown conflicting results. The aim of this study was to use \u2018real-world\u2019 data to evaluate the effect and side effects of using methylphenidate in palliative cancer care with a focus on the late palliative phase and dose-response.\nMethod: A retrospective review of medical records from a palliative care unit in Sweden was performed to evaluate the effect and adverse events (AEs) of using methylphenidate to treat CRF. Univariable and multivariable regression was performed and odds ratio (OR) calculated. Adjustments were made for sex, age, cancer type, dose and starting treatment &lt;4 weeks before death.\nResults: Of the 2,419 screened patients, 112 had been treated with methylphenidate for CRF. The treatment was assessed as being effective in 51 patients (46%). Twenty-six patients (23%) experienced AEs that were generally mild, including anxiety, palpitations, and insomnia. Patients starting the treatment &lt;4 weeks before death (n = 54) were less likely to have an effect from treatment compared to those starting earlier; adjusted OR 0.24 (95% CI 0.10\u20130.55). Doses of 20 mg and above were well-tolerated and had a higher frequency of effect in the crude data but not after adjustment for confounding factors.\nConclusion: Methylphenidate is generally effective and well-tolerated for the treatment of CRF in palliative care. However, patients with a short life expectancy (&lt;4 weeks) seem to benefit less from the treatment regardless of age, cancer type and dose.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.24156","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T07:21:12Z","timestamp":1707808872000},"page":"9-16","source":"Crossref","is-referenced-by-count":2,"title":["Methylphenidate for treating fatigue in palliative cancer care \u2013 effect and side effects in real-world data from a palliative care unit"],"prefix":"10.2340","volume":"63","author":[{"given":"Agneta","family":"Almerud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Frisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caritha","family":"Klasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Bj\u00f6rkhem-Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"48978","doi-asserted-by":"crossref","unstructured":"Al Maqbali M, Al Sinani M, Al Naamani Z, Al Badi K, Tanash MI. Prevalence of fatigue in patients with cancer: a systematic review and meta-analysis. J Pain Symptom Manage. 2021;61(1):167\u201389 e14. https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.07.037","DOI":"10.1016\/j.jpainsymman.2020.07.037"},{"key":"48979","doi-asserted-by":"crossref","unstructured":"Bower JE. Cancer-related fatigue \u2013 mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597\u2013609. https:\/\/doi.org\/10.1038\/nrclinonc.2014.127","DOI":"10.1038\/nrclinonc.2014.127"},{"key":"48980","doi-asserted-by":"crossref","unstructured":"de Raaf PJ, de Klerk C, Timman R, Hinz A, van der Rijt CC. Differences in fatigue experiences among patients with advanced cancer, cancer survivors, and the general population. J Pain Symptom Manage. 2012;44(6):823\u201330. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.12.279","DOI":"10.1016\/j.jpainsymman.2011.12.279"},{"key":"48981","doi-asserted-by":"crossref","unstructured":"de Raaf PJ, de Klerk C, van der Rijt CC. Elucidating the behavior of physical fatigue and mental fatigue in cancer patients: a review of the literature. Psychooncology. 2013;22(9):1919\u201329. https:\/\/doi.org\/10.1002\/pon.3225","DOI":"10.1002\/pon.3225"},{"key":"48982","doi-asserted-by":"crossref","unstructured":"Hagelin CL, Wengstrom Y, Ahsberg E, Furst CJ. Fatigue dimensions in patients with advanced cancer in relation to time of survival and quality of life. Palliat Med. 2009;23(2):171\u20138. https:\/\/doi.org\/10.1177\/0269216308098794","DOI":"10.1177\/0269216308098794"},{"key":"48983","doi-asserted-by":"crossref","unstructured":"Klasson C, Helde Frankling M, Lundh Hagelin C, Bj\u00f6rkhem-Bergman L. Fatigue in cancer patients in palliative care \u2013 a review on pharmacological interventions. Cancers (Basel). 2021;13(5):985. https:\/\/doi.org\/10.3390\/cancers13050985","DOI":"10.3390\/cancers13050985"},{"key":"48984","doi-asserted-by":"crossref","unstructured":"Klasson C, Helde Frankling M, Warnqvist A, et al. Sex differences in the effect of vitamin D on fatigue in palliative cancer care \u2013 a post hoc analysis of the randomized, controlled trial \u2018Palliative-D\u2019. Cancers (Basel). 2022;14(3). https:\/\/doi.org\/10.3390\/cancers14030746","DOI":"10.3390\/cancers14030746"},{"key":"48985","doi-asserted-by":"crossref","unstructured":"Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6914","DOI":"10.1001\/jamaoncol.2016.6914"},{"key":"48986","doi-asserted-by":"crossref","unstructured":"M\u00fccke M, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev. 2015;5:CD006788. https:\/\/doi.org\/10.1002\/14651858.CD006788.pub3","DOI":"10.1002\/14651858.CD006788.pub3"},{"key":"48987","doi-asserted-by":"crossref","unstructured":"Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients \u2013 an EAPC approach. Palliat Med. 2008;22(1):13\u201332. https:\/\/doi.org\/10.1177\/0269216307085183","DOI":"10.1177\/0269216307085183"},{"key":"48988","unstructured":"Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park). 2000;14(11A):151-61."},{"key":"48989","doi-asserted-by":"crossref","unstructured":"Fabi A, Bhargava R, Fatigoni S, et al. Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol. 2020;31(6):713\u201323. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.016","DOI":"10.1016\/j.annonc.2020.02.016"},{"key":"48990","doi-asserted-by":"crossref","unstructured":"Bruera E, Yennurajalingam S, Palmer JL, et al. Methylphenidate and\/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31(19):2421\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.45.3696","DOI":"10.1200\/JCO.2012.45.3696"},{"key":"48991","doi-asserted-by":"crossref","unstructured":"Centeno C, Roji R, Portela MA, et al. Improved cancer-related fatigue in a randomised clinical trial: methylphenidate no better than placebo. BMJ Support Palliat Care. 2022;12(2):226\u201334. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002454","DOI":"10.1136\/bmjspcare-2020-002454"},{"key":"48992","doi-asserted-by":"crossref","unstructured":"Escalante CP, Meyers C, Reuben JM, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014;20(1):8\u201314. https:\/\/doi.org\/10.1097\/PPO.0000000000000018","DOI":"10.1097\/PPO.0000000000000018"},{"key":"48993","doi-asserted-by":"crossref","unstructured":"Mitchell GK, Hardy JR, Nikles CJ, et al. The effect of methylphenidate on fatigue in advanced cancer: an aggregated N-of-1 trial. J Pain Symptom Manage. 2015;50(3):289\u201396. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.03.009","DOI":"10.1016\/j.jpainsymman.2015.03.009"},{"key":"48994","doi-asserted-by":"crossref","unstructured":"Pedersen L, Lund L, Petersen MA, Sjogren P, Groenvold M. Methylphenidate as needed for fatigue in patients with advanced cancer. A prospective, double-blind, and placebo-controlled study. J Pain Symptom Manage. 2020;60(5):992\u20131002. https:\/\/doi.org\/10.1016\/j.jpainsymman.2020.05.023","DOI":"10.1016\/j.jpainsymman.2020.05.023"},{"key":"48995","doi-asserted-by":"crossref","unstructured":"Richard PO, Fleshner NE, Bhatt JR, Hersey KM, Chahin R, Alibhai SM. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. BJU Int. 2015;116(5):744\u201352. https:\/\/doi.org\/10.1111\/bju.12755","DOI":"10.1111\/bju.12755"},{"key":"48996","doi-asserted-by":"crossref","unstructured":"Roth AJ, Nelson C, Rosenfeld B, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116(21):5102\u201310. https:\/\/doi.org\/10.1002\/cncr.25424","DOI":"10.1002\/cncr.25424"},{"key":"48997","doi-asserted-by":"crossref","unstructured":"Hovey E, de Souza P, Marx G, et al. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer. 2014;22(5):1233\u201342. https:\/\/doi.org\/10.1007\/s00520-013-2076-0","DOI":"10.1007\/s00520-013-2076-0"},{"key":"48998","doi-asserted-by":"crossref","unstructured":"Lee EQ, Muzikansky A, Drappatz J, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016;18(6):849\u201354. https:\/\/doi.org\/10.1093\/neuonc\/now007","DOI":"10.1093\/neuonc\/now007"},{"key":"48999","doi-asserted-by":"crossref","unstructured":"Spathis A, Fife K, Blackhall F, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32(18):1882\u20138. https:\/\/doi.org\/10.1200\/JCO.2013.54.4346","DOI":"10.1200\/JCO.2013.54.4346"},{"key":"49000","doi-asserted-by":"crossref","unstructured":"Auret KA, Schug SA, Bremner AP, Bulsara M. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage. 2009;37(4):613\u201321. https:\/\/doi.org\/10.1016\/j.jpainsymman.2008.03.016","DOI":"10.1016\/j.jpainsymman.2008.03.016"},{"key":"49001","doi-asserted-by":"crossref","unstructured":"Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001;18(6):403\u20137. https:\/\/doi.org\/10.1177\/104990910101800610","DOI":"10.1177\/104990910101800610"},{"key":"49002","unstructured":"Bjorkhem-Bergman L, Wallin C. [Methylphenidate and cannabinoids may have a place in palliative care. Literature review and clinical experience provides evidence]. Lakartidningen. 2013;110(32\u201333):1409\u201311."},{"key":"49003","doi-asserted-by":"crossref","unstructured":"Storebo OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885. https:\/\/doi.org\/10.1002\/14651858.CD009885.pub2","DOI":"10.1002\/14651858.CD009885.pub2"},{"key":"49004","doi-asserted-by":"crossref","unstructured":"Kapur A. Is methylphenidate beneficial and safe in pharmacological cognitive enhancement? CNS Drugs. 2020;34(10):1045\u201362. https:\/\/doi.org\/10.1007\/s40263-020-00758-w","DOI":"10.1007\/s40263-020-00758-w"},{"key":"49005","doi-asserted-by":"crossref","unstructured":"Kis B, Lucke C, Abdel-Hamid M, Hessmann P, Graf E, Berger M, et al. Safety profile of methylphenidate under long-term treatment in adult ADHD patients \u2013 results of the COMPAS study. Pharmacopsychiatry. 2020;53(6):263\u201371. https:\/\/doi.org\/10.1055\/a-1207-9851","DOI":"10.1055\/a-1207-9851"},{"key":"49006","doi-asserted-by":"crossref","unstructured":"Seeman P. Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol. 2013;23(9):999\u20131009. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.06.005","DOI":"10.1016\/j.euroneuro.2013.06.005"},{"key":"49007","doi-asserted-by":"crossref","unstructured":"Sterpu B, Lindman P, Bjorkhem-Bergman L. A comparative study on decision and documentation of refraining from resuscitation in two medical home care units in Sweden. BMC Palliat Care. 2019;18(1):80. https:\/\/doi.org\/10.1186\/s12904-019-0472-z","DOI":"10.1186\/s12904-019-0472-z"},{"key":"49008","doi-asserted-by":"crossref","unstructured":"Flatt T. A new definition of aging? Front Genet. 2012;3:148. https:\/\/doi.org\/10.3389\/fgene.2012.00148","DOI":"10.3389\/fgene.2012.00148"},{"key":"49009","doi-asserted-by":"crossref","unstructured":"Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA. 2003;289(18):2387\u201392. https:\/\/doi.org\/10.1001\/jama.289.18.2387","DOI":"10.1001\/jama.289.18.2387"},{"key":"49010","doi-asserted-by":"crossref","unstructured":"Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2\/D-3 receptors. Synapse. 2002;46(3):170\u201388. https:\/\/doi.org\/10.1002\/syn.10128","DOI":"10.1002\/syn.10128"},{"key":"49011","doi-asserted-by":"crossref","unstructured":"Hoenemeyer TW, Kaptchuk TJ, Mehta TS, Fontaine KR. Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial. Sci Rep. 2018;8(1):2784. https:\/\/doi.org\/10.1038\/s41598-018-20993-y","DOI":"10.1038\/s41598-018-20993-y"},{"key":"49012","doi-asserted-by":"crossref","unstructured":"Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit\/hyperactivity disorder: a meta-analysis. JAMA Pediatr. 2019;173(7):630\u20139. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.0905","DOI":"10.1001\/jamapediatrics.2019.0905"},{"key":"49013","doi-asserted-by":"crossref","unstructured":"Mattos P, Louza MR, Palmini AL, de Oliveira IR, Rocha FL. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study. J Atten Disord. 2013;17(5):444\u20138. https:\/\/doi.org\/10.1177\/1087054711434772","DOI":"10.1177\/1087054711434772"},{"key":"49014","doi-asserted-by":"crossref","unstructured":"Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7\u20138):579\u201389. https:\/\/doi.org\/10.1016\/j.neuropharm.2009.07.026","DOI":"10.1016\/j.neuropharm.2009.07.026"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/24156\/45326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/24156\/45326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:05:11Z","timestamp":1756404311000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/24156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.24156","relation":{},"ISSN":["1651-226X","0284-186X"],"issn-type":[{"value":"1651-226X","type":"electronic"},{"value":"0284-186X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,13]]}}}